In a remarkable move towards advancing precision medicine, Zydus and Guardant Health have entered into a co-marketing agreement, aiming to promote the Guardant360 portfolio of liquid and tissue biopsy tests across India and Nepal. This collaboration, as announced through an exchange filing, highlights the commitment to enhancing patient outcomes and the field of precision oncology in the region.

Comprehensive Genomic Profiling at the Forefront: The tests highlighted in this partnership include Guardant360 and Guardant360 TissueNext, offering comprehensive genomic profiling (CGP), along with the Guardant360 Response test designed for monitoring treatment response. These cutting-edge tests play a crucial role in providing oncologists with valuable insights to make informed decisions for patients dealing with advanced cancer.

Addressing a Growing Health Challenge: Cancer poses a significant health challenge in India and Nepal, with alarming statistics revealing that one out of nine Indians may develop cancer in their lifetime, and over 20,000 individuals in Nepal are diagnosed with cancer annually. Simranjit Singh, CEO of Guardant Health Asia, Middle East, and Africa, emphasizes the pressing need to tackle this issue.

Innovative Solutions for Improved Patient Care: Guardant360, a minimally invasive liquid biopsy test, stands out by offering comprehensive genomic profiling of solid tumours through the analysis of circulating tumour DNA (ctDNA) from a simple blood draw. Guardant360 TissueNext complements this by providing CGP results from a tumour tissue biopsy, offering actionable information to doctors when tissue testing is necessary. The Guardant360 Response test serves as a vital monitoring tool, enabling oncologists to track a patient's treatment response over time.

A Collective Step Toward Precision Medicine: By pooling their resources and expertise, Zydus and Guardant Health aspire to empower oncologists with the necessary tools to navigate treatment decisions effectively. This collaboration signifies a shared dedication to advancing precision medicine and ultimately making a positive impact on cancer care in the region.

As India and Nepal grapple with the growing burden of cancer cases, initiatives like these are pivotal in steering the healthcare landscape towards innovative solutions and improved patient care. The collaboration between Zydus and Guardant Health marks a significant stride in the realm of precision medicine, offering a ray of hope for cancer patients in India and Nepal. With a focus on comprehensive genomic profiling through tests like Guardant360 and Guardant360 TissueNext, the collaboration addresses the pressing need for precise and informed decision-making in oncology. The inclusion of the Guardant360 Response test further underlines the commitment to monitoring treatment responses over time, ensuring a tailored approach to each patient's journey.